Objetivo
While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer.
Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individual’s risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells – currently collected within cervical cancer screening – provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Müllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of “P4 Medicine” (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tool’s output into personalised recommendations for screening and prevention of female cancers.
Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.
Ámbito científico
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicinephysiologycytology
- medical and health sciencesclinical medicineoncologycervical cancer
- social scienceseconomics and businesseconomicshealth economics
- medical and health scienceshealth sciencesinfectious diseasesDNA viruses
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-PHC-2014-two-stage
Régimen de financiación
RIA - Research and Innovation actionCoordinador
WC1E 6BT London
Reino Unido
Ver en el mapa
Participantes (14)
17177 Stockholm
Ver en el mapa
116 36 Praha 1
Ver en el mapa
5021 Bergen
Ver en el mapa
20121 Milano
Ver en el mapa
SO16 6YD Southampton
Ver en el mapa
Entidad jurídica distinta de un subcontratista que está afiliada o vinculada jurídicamente con un participante. Dicha entidad lleva a cabo su trabajo en las condiciones establecidas en el acuerdo de subvención, proporciona bienes o presta servicios para la acción, pero no firma dicho acuerdo. El tercero acata las normas aplicables a su participante en virtud del acuerdo de subvención en lo que respecta a la subvencionalidad de los costes y el control de los gastos.
SO17 1BJ Southampton
Ver en el mapa
80539 Muenchen
Ver en el mapa
WC1E 7HT London
Ver en el mapa
La participación finalizó
CB2 1TN Cambridge
Ver en el mapa
3015 GD Rotterdam
Ver en el mapa
6020 INNSBRUCK
Ver en el mapa
80539 Munchen
Ver en el mapa
La participación finalizó
LN1 1XW Lincoln
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.
78467 Konstanz
Ver en el mapa